Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC candidates across a range of solid/hematological cancers Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline Cash on hand expected to be sufficient to fund planned operations into September 2025 BOSTON and LONDON, April 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-fun

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several executive leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVA®, Repatha®, and ELIQUIS® Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company's Board of Directors BOSTON and LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a biotechnology company developing next-generation preci

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective December 16, 2024. Dr. Patel has served as interim Chief Executive Officer since May 2024. Additionally, the Company announced it has appointed Abizer Gaslightwala to its Board of Directors, effective December 16, 2024. Michael Grissinger, a member of the Board of Directors, provided notice of his resignation on December 16, 2024. "Since beginning my role as interim CEO in May 2024, we ha

BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck is a seasoned executive with over 20 years of experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product development and regulatory filings in the U.S. and Europe. "We are pleased with the continued evolution and progress made across multiple fronts. We believe that adding expertise to our leadership team is a key component of ensuring continued progress and importantly our ability to build upon momentu

BOSTON and LONDON, Sept. 17, 2024 (GLOBE NEWSWIRE) --  Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, announces the appointment of Rob Bazemore, experienced life sciences leader, to the Akari Board of Directors effective September 17, 2024. "I am very honored to have the opportunity to work with this distinguished board of directors to advance the portfolio opportunities," said Mr. Bazemore. "Focusing on Akari's novel lead asset, nomacopan, as well as Peak's innovative antibody-drug-conjugate (ADC) platform in oncology, has the opportunity to bring significant value both for patients and fo

Samir R. Patel, M.D. Appointed Interim CEO; Interim CEO Employment Contract Demonstrates Alignment with Shareholders Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Existing Investors Support the Company with Issuance of $1 Million in Unsecured Convertible Notes Secured $7.6 Million in Upsized Financing Round Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy BOSTON and LONDON, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an innovative biotechnology company developing advanced therapies for autoimmune and inf

Entered into a Definitive Merger Agreement with Peak Bio; Expected to Close in the Third Quarter of 2024 Samir R. Patel, M.D. Appointed Interim CEO Plan for Prioritization of Peak Bio's ADC Cancer Therapeutic Platform Technology and Akari's PAS-nomacopan for Geographic Atrophy Implementation of Restructuring Plan to Reduce Operating Costs Existing Investors Support the Company with Issuance of $1 million in Unsecured Convertible Notes BOSTON and LONDON, May 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, has reported financial results for the first quarter

BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced leadership changes, including the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. as interim CEO. Rachelle Jacques will step down as Akari's Chief Executive Officer effective today. Melissa Bradford-Klug will step down as Akari's Chief Operating Officer effective today. In connection with Ms. Jacques' departure, Akari's board of directors (the "Board") has appointed Dr. Patel as Interim Chief Executive Officer. Dr. Patel has served as a member of the Board sinc

NEW YORK and BOSTON, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the appointment of experienced life sciences entrepreneur Samir R. Patel, M.D. to the Akari Board of Directors. "Samir is a long-time investor in Akari and brings to us broad life sciences experience and a track record of multiple successful startup companies. I am pleased to welcome him to our Board of Directors at this important time in our company's development," said Ray Prudo, M.D., Akari Chairman. "I am truly honored to have this opportunity to further demonstrate my c

Advancing development of novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads to treat multiple cancer tumors Rounding out executive team with deep oncology experience by appointing new Head of Business Development - Oncology BOSTON and LONDON, May 15, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing novel Antibody Drug Conjugates (ADCs) with immuno-oncology payloads for the treatment of cancer, today reported its financial results for the first quarter ended March 31, 2025 and provided a corporate update. "We remain laser focused on becoming a key player in the ADC space and advancing our novel ADC platform built around i

Global expertise in establishing and executing transformative transactions which have led to multiple approved therapeutic products Successful track record across oncology therapeutics including ADCs and antibody therapies ranging from early discovery to pre-clinical/clinical stage 25+ year-career experience bolsters Company's efforts to address growing, high-value ADC market and maximize opportunities for non-dilutive capital BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced the appointment of Mark F. Kubik as Head of Business Development

Biotechnology and pharmaceutical industry veteran, Abizer Gaslightwala, shares his vision for Akari moving forward Access the video here BOSTON and LONDON, April 22, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced the release of a corporate update video featuring newly appointed President and Chief Executive Officer, Abizer Gaslightwala. The video is now available on the Presentations page under the Investors section of the Company's website (www.akaritx.com). About Akari Therapeutics Akari Therapeut

Advancing development of next-generation precision Antibody Drug Conjugates (ADCs) to address multiple indications across a range of cancer types Continued progress of lead program, AKTX-101, for the treatment of solid tumors Platform technology to fuel pipeline with ability to generate novel ADC candidates across a range of solid/hematological cancers Leveraging opportunities for non-dilutive capital through partnering of legacy pipeline Cash on hand expected to be sufficient to fund planned operations into September 2025 BOSTON and LONDON, April 16, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-fun

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several executive leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVA®, Repatha®, and ELIQUIS® Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company's Board of Directors BOSTON and LONDON, March 20, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX) ("Akari" or the "Company"), a biotechnology company developing next-generation preci

BOSTON and LONDON, March 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADCs) for the treatment of cancer, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $7.6 million in gross proceeds. With these funds the Company will focus on investing in its novel spliceosome inhibitor payload ADC technology platform, seeking license partners for its TROP-2 ADC program, and monetizing non-core assets. "We were very pleased that the private placement was supported by existing investors

On-demand video webcast now available here BOSTON and LONDON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced it participated in the Virtual Investor "Top 5 for ‘25" On-Demand Conference. As part of the event, Dr. Samir Patel, President and Chief Executive Officer of Akari Therapeutics, presented the top five reasons of why he believes the investment community and industry colleagues should pay attention to Akari in 2025. The on-demand video webcast is now accessible for viewing here and on the Investors section o

Innovative targeted oncology company built on next-generation ADCs and a novel discovery engine Connect with the Company on Webull here BOSTON and LONDON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing next-generation precision bi-functional antibody drug conjugates (ADC) for the treatment of cancer, today announced that it is now participating on the Webull Corporate Connect Service (CCS) platform. Akari's portal on the Webull CCS aims to provide an additional line of communication for shareholders and interested investors and enhance transparency with its growing shareholder base. Through Webull, the Company will relea

Samir R. Patel, M.D., appointed as Chief Executive Officer Abizer Gaslightwala appointed to Board of Directors BOSTON and LONDON, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) today announced the appointment of Samir R. Patel, M.D., as Chief Executive Officer, effective December 16, 2024. Dr. Patel has served as interim Chief Executive Officer since May 2024. Additionally, the Company announced it has appointed Abizer Gaslightwala to its Board of Directors, effective December 16, 2024. Michael Grissinger, a member of the Board of Directors, provided notice of his resignation on December 16, 2024. "Since beginning my role as interim CEO in May 2024, we ha

BOSTON and LONDON, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) today announced the appointment of Torsten Hombeck, Ph.D. as Chief Financial Officer, effective December 16, 2024. Dr. Hombeck is a seasoned executive with over 20 years of experience in the biotechnology industry, finance, capital markets and M&A transactions, as well as clinical and commercial product development and regulatory filings in the U.S. and Europe. "We are pleased with the continued evolution and progress made across multiple fronts. We believe that adding expertise to our leadership team is a key component of ensuring continued progress and importantly our ability to build upon momentu